Free Trial

Ocular Therapeutix (OCUL) Competitors

Ocular Therapeutix logo
$11.84 -0.36 (-2.95%)
Closing price 10/17/2025 04:00 PM Eastern
Extended Trading
$11.84 0.00 (0.00%)
As of 10/17/2025 06:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

OCUL vs. ABVX, RNA, CYTK, MRUS, RYTM, CRSP, GRFS, NUVL, AXSM, and LEGN

Should you be buying Ocular Therapeutix stock or one of its competitors? The main competitors of Ocular Therapeutix include Abivax (ABVX), Avidity Biosciences (RNA), Cytokinetics (CYTK), Merus (MRUS), Rhythm Pharmaceuticals (RYTM), CRISPR Therapeutics (CRSP), Grifols (GRFS), Nuvalent (NUVL), Axsome Therapeutics (AXSM), and Legend Biotech (LEGN). These companies are all part of the "pharmaceutical products" industry.

Ocular Therapeutix vs. Its Competitors

Abivax (NASDAQ:ABVX) and Ocular Therapeutix (NASDAQ:OCUL) are both mid-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, analyst recommendations, profitability, dividends and valuation.

Abivax has a beta of 0.39, suggesting that its stock price is 61% less volatile than the S&P 500. Comparatively, Ocular Therapeutix has a beta of 1.45, suggesting that its stock price is 45% more volatile than the S&P 500.

Abivax has higher earnings, but lower revenue than Ocular Therapeutix.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AbivaxN/AN/A-$190.71MN/AN/A
Ocular Therapeutix$63.72M32.33-$193.51M-$1.28-9.25

47.9% of Abivax shares are owned by institutional investors. Comparatively, 59.2% of Ocular Therapeutix shares are owned by institutional investors. 2.3% of Ocular Therapeutix shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Abivax had 4 more articles in the media than Ocular Therapeutix. MarketBeat recorded 9 mentions for Abivax and 5 mentions for Ocular Therapeutix. Ocular Therapeutix's average media sentiment score of 0.83 beat Abivax's score of 0.44 indicating that Ocular Therapeutix is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Abivax
1 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
Ocular Therapeutix
2 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Abivax has a net margin of 0.00% compared to Ocular Therapeutix's net margin of -382.51%. Abivax's return on equity of 0.00% beat Ocular Therapeutix's return on equity.

Company Net Margins Return on Equity Return on Assets
AbivaxN/A N/A N/A
Ocular Therapeutix -382.51%-71.92%-49.36%

Abivax currently has a consensus price target of $114.25, suggesting a potential upside of 23.21%. Ocular Therapeutix has a consensus price target of $22.63, suggesting a potential upside of 91.09%. Given Ocular Therapeutix's higher probable upside, analysts clearly believe Ocular Therapeutix is more favorable than Abivax.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Abivax
1 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.91
Ocular Therapeutix
1 Sell rating(s)
1 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.75

Summary

Abivax and Ocular Therapeutix tied by winning 7 of the 14 factors compared between the two stocks.

Get Ocular Therapeutix News Delivered to You Automatically

Sign up to receive the latest news and ratings for OCUL and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OCUL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OCUL vs. The Competition

MetricOcular TherapeutixMED IndustryMedical SectorNASDAQ Exchange
Market Cap$2.12B$2.63B$6.09B$10.48B
Dividend YieldN/A57.79%5.73%4.80%
P/E Ratio-9.2522.9984.5227.09
Price / Sales32.33552.73521.80181.08
Price / CashN/A168.7137.1661.22
Price / Book5.895.3212.246.52
Net Income-$193.51M$33.06M$3.32B$276.75M
7 Day Performance0.51%2.44%1.25%1.97%
1 Month Performance-6.85%6.46%6.28%2.23%
1 Year Performance4.50%-5.42%59.92%35.58%

Ocular Therapeutix Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OCUL
Ocular Therapeutix
4.3219 of 5 stars
$11.84
-3.0%
$22.63
+91.1%
+6.8%$2.12B$63.72M-9.25230Gap Down
ABVX
Abivax
3.5043 of 5 stars
$95.63
+2.0%
$114.25
+19.5%
+795.9%$7.30BN/A0.0061Short Interest ↓
RNA
Avidity Biosciences
2.5493 of 5 stars
$48.96
-1.6%
$68.32
+39.5%
-1.3%$7.26B$10.90M-13.75190News Coverage
Insider Trade
CYTK
Cytokinetics
3.8489 of 5 stars
$59.59
-0.7%
$76.64
+28.6%
+7.2%$7.18B$18.47M-11.68250Trending News
Insider Trade
MRUS
Merus
1.402 of 5 stars
$94.85
+0.5%
$93.12
-1.8%
+83.4%$7.14B$36.13M-17.2537Short Interest ↓
RYTM
Rhythm Pharmaceuticals
2.8904 of 5 stars
$100.77
0.0%
$106.64
+5.8%
+116.1%$6.70B$130.13M-33.48140News Coverage
Analyst Forecast
CRSP
CRISPR Therapeutics
2.2295 of 5 stars
$68.29
-6.5%
$71.71
+5.0%
+43.2%$6.65B$37.31M-12.58460Trending News
Analyst Forecast
Insider Trade
Analyst Revision
GRFS
Grifols
3.764 of 5 stars
$9.45
+1.4%
$10.30
+9.0%
+12.3%$6.41B$7.81B8.0823,822
NUVL
Nuvalent
2.8066 of 5 stars
$89.75
+1.9%
$118.89
+32.5%
-9.4%$6.35BN/A-18.3240Trending News
Analyst Forecast
Insider Trade
AXSM
Axsome Therapeutics
4.73 of 5 stars
$121.15
-0.5%
$177.93
+46.9%
+37.1%$6.07B$385.69M-23.90380Analyst Revision
LEGN
Legend Biotech
3.0544 of 5 stars
$32.85
+3.6%
$69.25
+110.8%
-25.8%$5.85B$627.24M-37.332,609News Coverage
Analyst Forecast
High Trading Volume

Related Companies and Tools


This page (NASDAQ:OCUL) was last updated on 10/18/2025 by MarketBeat.com Staff
From Our Partners